FDA Approves Jardiance for Adults With Chronic Kidney Disease

FDA approved Jardiance, a prescription medicine, for the treatment of chronic kidney disease.

In a press release, Eli Lilly explained that the drug, made in partnership with Boehringer Ingelheim, may now be used to reduce the risk of sustained decline in estimated glomerular filtration rate, end-stage kidney disease, cardiovascular death, and hospitalization.

The medicine is not recommended for use with in patients who require intravenous immunosuppressive therapy or those with polycystic kidney disease.

"CKD affects more than one in seven adults in the U.S., 90% of whom are undiagnosed, and it remains a significantly under-recognized public health crisis," said Mohamed Eid, M.D., M.P.H., M.H.A., vice president, Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc., in a press release. "Hospitalizations account for a third to a half of total healthcare costs for this population, and disease progression often leads to serious cardiovascular complications and kidney failure, which can require dialysis or transplantation. Given the clinically demonstrated benefits of Jardiance, we are proud to now be able to offer this option to adults with CKD at risk for progression."

Jardiance is used to lower blood sugar, reduce the risk of cardiovascular death in adults with type 2 diabetes, reduce the risk of cardiovascular death for patients whose hearts cannot pump enough blood, and reduce the risk of worsening kidney disease. The drug generated $6.2 billion in sales in 2022.

Source

(Sept. 22, 2023); Lilly; US FDA approves Jardiance® for the treatment of adults with chronic kidney disease; https://investor.lilly.com/news-releases/news-release-details/us-fda-approves-jardiancer-treatment-adults-chronic-kidney